Compare Amgen, Inc. (AMGN) vs KE Holdings Inc (BEKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs KE Holdings Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while KE Holdings Inc trades at $15.75 (market cap $17.21B). The key difference: Amgen, Inc. is far larger — about 11.4× KE Holdings Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BEKE | |
|---|---|---|
Market Cap | $196.12B | $17.21B |
Sector | Health | Technology |
52-Week High | $388.16 | $20.36 |
52-Week Low | $271.18 | $14.26 |
Enterprise Value | $241.41B | $12.99B |
Dividend Yield | 2.77% | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BEKE trades at $15.57, up 2.1% today, with a bearish technical signal despite recent earnings beat. The company reported strong Q1 2026 results with EPS of $0.20 beating expectations of $0.14, driven by improved profitability despite lower revenue. Analyst consensus remains overwhelmingly bullish with 91.7% buy ratings, while technical indicators show oversold conditions suggesting potential reversal.
The outlook appears constructive given improving profitability and positive analyst sentiment, though risks include China's property market volatility and recent cash flow challenges. The stock's current valuation at P/E 35.6x reflects growth expectations, with potential upside if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
